Investigators from Fujian Medical University Report New Data on Non-Small Cell Lung Cancer (Efficacy Analysis of Immunotherapy-based Combinations for Patients With Egfr-mutant Advanced Non-small Cell Lung Cancer After Tki Failure).

A study conducted by investigators from Fujian Medical University in China focused on the efficacy of immunotherapy-based combinations for patients with EGFR-mutant advanced non-small cell lung cancer after TKI failure. The research found that patients with low ECOG-PS scores, T790M-negative status, or high PD-L1 expression may benefit from PD-1 inhibitor-based combinations. The study suggested that combining immunotherapy with chemotherapy and antiangiogenic agents could be a promising treatment option for these patients. [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)